Using plasma of patients with melanoma as a source of sEV isolated by SEC in step1, this strategy makes use of mAbs specific for an epitope of Chondroitin Sulfate Proteoglycan-4 (CSPG4), which is overexpressed on most melanoma cells and on melanoma cell-derived sEV but not on non-malignant cells or sEV these non-malignant cells produce [59,60,61]. Here, CSPG4 is linked to melanoma.